These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24854402)

  • 41. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
    Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
    Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
    Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
    Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple Mechanisms Drive Resistance to ALK Inhibitors in Lung Cancer.
    Cancer Discov; 2015 May; 5(5):OF10. PubMed ID: 25790980
    [No Abstract]   [Full Text] [Related]  

  • 50. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 51. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A; Wood K; Salgia R
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
    Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R
    Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R
    Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating Tumor Cells with Aberrant
    Pailler E; Oulhen M; Borget I; Remon J; Ross K; Auger N; Billiot F; Ngo Camus M; Commo F; Lindsay CR; Planchard D; Soria JC; Besse B; Farace F
    Cancer Res; 2017 May; 77(9):2222-2230. PubMed ID: 28461563
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    Shaw AT; Friboulet L; Leshchiner I; Gainor JF; Bergqvist S; Brooun A; Burke BJ; Deng YL; Liu W; Dardaei L; Frias RL; Schultz KR; Logan J; James LP; Smeal T; Timofeevski S; Katayama R; Iafrate AJ; Le L; McTigue M; Getz G; Johnson TW; Engelman JA
    N Engl J Med; 2016 Jan; 374(1):54-61. PubMed ID: 26698910
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
    Cameron L; Solomon B
    Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation.
    Kay M; Dehghanian F
    J Mol Model; 2017 Oct; 23(11):323. PubMed ID: 29067524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.